Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some advanced cancers that previously had no therapeutic options. Chimeric antigen receptor T-cell (CAR T-cell) therapy is one immunotherapeutic approach that has recently garnered significant attention. In brief, CAR T-cell therapy involves removing a patient’s immune cells, altering them in a laboratory setting to make them better primed to detect and kill cancer cells, and delivering the modified cells back to the patient.
A recent study published in the New England Journal of Medicine shows exciting new evidence of the benefits of CAR T cell therapy. The study (NCT04404660) tested the treatment modality called obecabtagene autoleucel (obe-cel), a CAR T-cell therapy that recognizes CD19, a marker expressed on leukemia cells. Unlike other CAR T-cell modalities used to treat leukemia, obe-cel recognizes the CD19 marker with only “intermediate affinity” instead of the “high affinity” recognition of comparable therapies. Researchers suspected the lower affinity associated with obe-cel would correlate with reduced adverse effects experienced by patients receiving other CAR T-cell therapies.
The phase 1b-2 multicenter study, which included 153 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), revealed promising results. Of the 127 patients who received at least one infusion of obe-cel, 77% experienced remission, with 55% achieving complete remission. The observed remission rates were significantly higher than expected, indicating notable efficacy of the treatment.
Leave a reply